Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Treasury Shares (2016 - 2025)

Akebia Therapeutics has reported Treasury Shares over the past 11 years, most recently at $330622.0 for Q4 2025.

  • Quarterly Treasury Shares fell 74.98% to $330622.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330622.0 through Dec 2025, down 74.98% year-over-year, with the annual reading at $330622.0 for FY2025, 74.98% down from the prior year.
  • Treasury Shares was $330622.0 for Q4 2025 at Akebia Therapeutics, down from $6.2 million in the prior quarter.
  • Over five years, Treasury Shares peaked at $162000.0 in Q4 2015 and troughed at $162000.0 in Q4 2015.
  • The 5-year median for Treasury Shares is $1.7 million (2024), against an average of $2.4 million.
  • Year-over-year, Treasury Shares surged 685.89% in 2024 and then crashed 74.98% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $4.6 million in 2021, then grew by 24.59% to $5.7 million in 2022, then tumbled by 41.14% to $3.3 million in 2023, then plummeted by 60.43% to $1.3 million in 2024, then crashed by 74.98% to $330622.0 in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Treasury Shares are $330622.0 (Q4 2025), $6.2 million (Q3 2025), and $476268.0 (Q2 2025).